To assess whether patients exhibiting baseline ocular hypertension independent of anti-VEGF therapy are more susceptible to a reduction in outflow facility in response to anti-VEGF, patients were divided based on IOP of the uninjected eye into an ocular hypertensive group (IOP >21 mm Hg, n = 5) and a normotensive group (IOP ≤ 21 mm Hg, n = 37). This evidence concerns the gene VEGFA and ocular hypertension.